<DOC>
	<DOCNO>NCT02565732</DOCNO>
	<brief_summary>This safety efficacy study botulinum toxin type A subject primary axillary hyperhidrosis .</brief_summary>
	<brief_title>Safety Efficacy Botulinum Toxin Type A Topical Gel Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Primary axillary hyperhidrosis Female male , 18 year age older good general health Excessive sweating interferes daily life activity score 3 4 HDSS Screening Baseline Axillary sweat production least 50 mg/5 min measure gravimetrically Any neurological condition , may place subject increase risk exposure botulinum toxin type A amyotrophic lateral sclerosis motor neuropathy , LambertEaton syndrome , Myasthenia gravis Muscle weakness paralysis , particularly upper extremity Active skin disease irritation disrupt barrier treatment area Undergone procedure may affect axillary area Treatment botulinum toxin type A axilla last 9 month anywhere body last 6 month Any prior axillary use antihyperhidrosis medical device If menopausal symptom menopause sweat flushing within last year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>